Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26647931 | 0.87 | CYP1A2 (0.39) | MEN1POLBKMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL26647934 | 0.87 | CYP1A2 (0.39) | MEN1POLBKMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL30243990 | 0.87 | MAPT (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL27395092 | 0.87 | MAPT (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL21962632 | 0.83 | CA2 (0.43) | — | |
| SCHEMBL1969671 | 0.78 | TARBP2 (0.36) | MEN1KMT2ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL22502175 | 0.75 | RIPK1 (0.43) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22502174 | 0.75 | RIPK1 (0.43) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL21979526 | 0.74 | CYP26A1 (0.43) | KMT2AALDH1A1KDM4ECNR2 | |
| SCHEMBL21979511 | 0.74 | CYP26A1 (0.43) | KMT2AALDH1A1KDM4ECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MEN1 3277/4885POLB 4639/4885KMT2A 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.